Intertrigo-Like Eruption Induced by Cetuximab: A Novel EGFR Inhibitor-Associated Toxicity

Targeted therapy has emerged as one of the most significant developments in cancer treatment in recent years. Patients with advanced, recurring, or metastatic cancer are treated with agents that target the epidermal growth factor receptor (EGFR). One of the most prevalent adverse reactions of EGFR inhibitors is skin damage. We report on a 70-year-old male patient with metastatic colorectal cancer who experienced an intertrigo-like eruption while receiving topical corticosteroid treatment as part of molecular target therapy with cetuximab. After being diagnosed in 2014, the patient had surgery. The surgical anastomosis (total dose = 50.4 Gy/dose per fraction = 1.8 Gy) and pelvic lymph nodes (total dose = 45 Gy; dose per fraction = 1.8 Gy) were treated with adjuvant radiochemotherapy in 2014. He then underwent four cycles of chemotherapy using the folinic acid, fluorouracil, and oxaliplatin scheme. The patient began chemotherapy in 2016 using the folinic acid, fluorouracil, and irinotecan scheme in conjunction with cetuximab 250 mg/sq. m weekly (for 6 cycles) due to the development of the illness as seen by fluorodeoxyglucose-positron emission tomography/CT. Owing to the stability of his condition, he resumed weekly cetuximab maintenance therapy, which is currently continuing with a partial response. After four weeks, a full remission was achieved. According to the results of this study, it might be beneficial to think about premedication with corticosteroids for individuals who have already experienced an episode of intertrigo-like eruption.